Forty‐Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Background. Challenges in the diagnosis and classification of cholangiocarcinoma have made it difficult to quantify the true incidence of this highly aggressive malignancy. Methods. We analyzed the Surveillance, Epidemiology, and End Results data to assess long‐term trends in the age‐standardized in...
Saved in:
| Published in | The oncologist (Dayton, Ohio) Vol. 21; no. 5; pp. 594 - 599 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Durham, NC, USA
AlphaMed Press
01.05.2016
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1083-7159 1549-490X 1549-490X |
| DOI | 10.1634/theoncologist.2015-0446 |
Cover
Loading…
| Abstract | Background.
Challenges in the diagnosis and classification of cholangiocarcinoma have made it difficult to quantify the true incidence of this highly aggressive malignancy.
Methods.
We analyzed the Surveillance, Epidemiology, and End Results data to assess long‐term trends in the age‐standardized incidence of intrahepatic and extrahepatic cholangiocarcinoma between 1973 and 2012, correcting for systematic coding errors. Because intrahepatic cholangiocarcinoma (ICC) may frequently be misdiagnosed as cancer of unknown primary (CUP), we also analyzed trends in the incidence of CUP.
Results.
Between 1973 and 2012, the reported U.S. incidence of ICC increased from 0.44 to 1.18 cases per 100,000, representing an annual percentage change (APC) of 2.30%; this trend has accelerated during the past decade to an APC of 4.36%. The incidence of extrahepatic cholangiocarcinoma increased modestly from 0.95 to 1.02 per 100,000 during the 40‐year period (APC, 0.14%). The incidence of CUP with histologic features potentially consistent with cholangiocarcinoma decreased by 51% between 1973 and 2012 (APC, −1.87%), whereas the incidence of CUP with squamous or nonepithelial histologic features increased modestly (APC, 0.42%).
Conclusion.
The recognized incidence of ICC in the U.S. continues to rise, whereas the incidence of ECC is stable. The incidence of CUP has fallen dramatically during the same time period.
Implications for Practice:
Clinical distinctions between cholangiocarcinoma (particularly intrahepatic cholangiocarcinoma [ICC]) and cancer of unknown primary (CUP) can be challenging. Recent discoveries have identified recurrent and potentially targetable genomic abnormalities in ICC, highlighting the importance of improving diagnosis. This study demonstrates that the incidence of ICC is increasing in the U.S., whereas the incidence of extrahepatic cholangiocarcinoma is stable. Concomitantly, the incidence of CUP has declined dramatically, suggesting that improved distinction between ICC and CUP may be a major driver of the increasing recognized incidence of ICC. The increasing incidence of ICC warrants further study of prevention and treatment approaches.
摘要
背景. 在胆管癌诊断和分类中存在的挑战使得这种高度侵袭性恶性肿瘤的真实发病率难以量化。
方法. 我们对监测、流行病学及预后 (SEER) 项目中的数据进行了分析, 评估1973‐2012年间肝内和肝外胆管癌年龄标化发病率的长期变化趋势 (根据系统编码误差校正) 。由于肝内胆管癌 (ICC) 常可能被误诊为原发部位不明的癌症 (CUP), 我们还对 CUP 发病率的变化趋势进行了分析。
结果. 1973‐2012 年间, 美国 ICC 发病率从 0.44/10 万人增长到 1.18/10 万人, 相当于年变化率 (APC) 为 2.30%。这一趋势在过去十年间进一步加剧, APC 提高至 4.36%。肝外胆管癌在 40 年间从 0.95/10 万人略增加到 1.02/10 万人 (APC: 0.14%)。 1973‐2012 年间, 组织学特征可能与胆管癌一致的 CUP 发病率下降了 51% (APC: ‐1.87%), 而鳞癌或非上皮性组织学特征的 CUP 的发病率则略有升高 (APC: 0.42%)。
结论. 在美国, 确诊的ICC发病率持续升高, 而ECC发病率保持稳定。而相同时期的CUP发病率则呈现大幅下降。The Oncologist 2016;21:594–599
对临床实践的提示: 对胆管癌[尤其是肝内胆管癌 (ICC) ]与原发部位不明的癌症 (CUP) 进行临床鉴别富有挑战性。 ICC 中近期识别出来的的复发和潜在靶位基因组异常强调了改进诊断的重要性。本研究证实美国的 ICC 发病率在持续升高, 而肝外胆管癌的发病率保持稳定。同一时期, CUP 的发病率则大幅下降, 提示 ICC 与 CUP 鉴别的进步可能是确诊的 ICC 发病率升高的主要驱动因素。 ICC 持续升高的发病率提示有必要针对其预防和治疗手段开展进一步的研究。
The recognized incidence of intrahepatic cholangiocarcinoma in the U.S. continues to rise, whereas the incidence of extrahepatic cholangiocarcinoma is stable. The incidence of carcinoma of unknown primary has fallen dramatically during the same time period. |
|---|---|
| AbstractList | Challenges in the diagnosis and classification of cholangiocarcinoma have made it difficult to quantify the true incidence of this highly aggressive malignancy.BACKGROUNDChallenges in the diagnosis and classification of cholangiocarcinoma have made it difficult to quantify the true incidence of this highly aggressive malignancy.We analyzed the Surveillance, Epidemiology, and End Results data to assess long-term trends in the age-standardized incidence of intrahepatic and extrahepatic cholangiocarcinoma between 1973 and 2012, correcting for systematic coding errors. Because intrahepatic cholangiocarcinoma (ICC) may frequently be misdiagnosed as cancer of unknown primary (CUP), we also analyzed trends in the incidence of CUP.METHODSWe analyzed the Surveillance, Epidemiology, and End Results data to assess long-term trends in the age-standardized incidence of intrahepatic and extrahepatic cholangiocarcinoma between 1973 and 2012, correcting for systematic coding errors. Because intrahepatic cholangiocarcinoma (ICC) may frequently be misdiagnosed as cancer of unknown primary (CUP), we also analyzed trends in the incidence of CUP.Between 1973 and 2012, the reported U.S. incidence of ICC increased from 0.44 to 1.18 cases per 100,000, representing an annual percentage change (APC) of 2.30%; this trend has accelerated during the past decade to an APC of 4.36%. The incidence of extrahepatic cholangiocarcinoma increased modestly from 0.95 to 1.02 per 100,000 during the 40-year period (APC, 0.14%). The incidence of CUP with histologic features potentially consistent with cholangiocarcinoma decreased by 51% between 1973 and 2012 (APC, -1.87%), whereas the incidence of CUP with squamous or nonepithelial histologic features increased modestly (APC, 0.42%).RESULTSBetween 1973 and 2012, the reported U.S. incidence of ICC increased from 0.44 to 1.18 cases per 100,000, representing an annual percentage change (APC) of 2.30%; this trend has accelerated during the past decade to an APC of 4.36%. The incidence of extrahepatic cholangiocarcinoma increased modestly from 0.95 to 1.02 per 100,000 during the 40-year period (APC, 0.14%). The incidence of CUP with histologic features potentially consistent with cholangiocarcinoma decreased by 51% between 1973 and 2012 (APC, -1.87%), whereas the incidence of CUP with squamous or nonepithelial histologic features increased modestly (APC, 0.42%).The recognized incidence of ICC in the U.S. continues to rise, whereas the incidence of ECC is stable. The incidence of CUP has fallen dramatically during the same time period.CONCLUSIONThe recognized incidence of ICC in the U.S. continues to rise, whereas the incidence of ECC is stable. The incidence of CUP has fallen dramatically during the same time period.Clinical distinctions between cholangiocarcinoma (particularly intrahepatic cholangiocarcinoma [ICC]) and cancer of unknown primary (CUP) can be challenging. Recent discoveries have identified recurrent and potentially targetable genomic abnormalities in ICC, highlighting the importance of improving diagnosis. This study demonstrates that the incidence of ICC is increasing in the U.S., whereas the incidence of extrahepatic cholangiocarcinoma is stable. Concomitantly, the incidence of CUP has declined dramatically, suggesting that improved distinction between ICC and CUP may be a major driver of the increasing recognized incidence of ICC. The increasing incidence of ICC warrants further study of prevention and treatment approaches.IMPLICATIONS FOR PRACTICEClinical distinctions between cholangiocarcinoma (particularly intrahepatic cholangiocarcinoma [ICC]) and cancer of unknown primary (CUP) can be challenging. Recent discoveries have identified recurrent and potentially targetable genomic abnormalities in ICC, highlighting the importance of improving diagnosis. This study demonstrates that the incidence of ICC is increasing in the U.S., whereas the incidence of extrahepatic cholangiocarcinoma is stable. Concomitantly, the incidence of CUP has declined dramatically, suggesting that improved distinction between ICC and CUP may be a major driver of the increasing recognized incidence of ICC. The increasing incidence of ICC warrants further study of prevention and treatment approaches. Background. Challenges in the diagnosis and classification of cholangiocarcinoma have made it difficult to quantify the true incidence of this highly aggressive malignancy. Methods. We analyzed the Surveillance, Epidemiology, and End Results data to assess long‐term trends in the age‐standardized incidence of intrahepatic and extrahepatic cholangiocarcinoma between 1973 and 2012, correcting for systematic coding errors. Because intrahepatic cholangiocarcinoma (ICC) may frequently be misdiagnosed as cancer of unknown primary (CUP), we also analyzed trends in the incidence of CUP. Results. Between 1973 and 2012, the reported U.S. incidence of ICC increased from 0.44 to 1.18 cases per 100,000, representing an annual percentage change (APC) of 2.30%; this trend has accelerated during the past decade to an APC of 4.36%. The incidence of extrahepatic cholangiocarcinoma increased modestly from 0.95 to 1.02 per 100,000 during the 40‐year period (APC, 0.14%). The incidence of CUP with histologic features potentially consistent with cholangiocarcinoma decreased by 51% between 1973 and 2012 (APC, −1.87%), whereas the incidence of CUP with squamous or nonepithelial histologic features increased modestly (APC, 0.42%). Conclusion. The recognized incidence of ICC in the U.S. continues to rise, whereas the incidence of ECC is stable. The incidence of CUP has fallen dramatically during the same time period. Implications for Practice: Clinical distinctions between cholangiocarcinoma (particularly intrahepatic cholangiocarcinoma [ICC]) and cancer of unknown primary (CUP) can be challenging. Recent discoveries have identified recurrent and potentially targetable genomic abnormalities in ICC, highlighting the importance of improving diagnosis. This study demonstrates that the incidence of ICC is increasing in the U.S., whereas the incidence of extrahepatic cholangiocarcinoma is stable. Concomitantly, the incidence of CUP has declined dramatically, suggesting that improved distinction between ICC and CUP may be a major driver of the increasing recognized incidence of ICC. The increasing incidence of ICC warrants further study of prevention and treatment approaches. 摘要 背景. 在胆管癌诊断和分类中存在的挑战使得这种高度侵袭性恶性肿瘤的真实发病率难以量化。 方法. 我们对监测、流行病学及预后 (SEER) 项目中的数据进行了分析, 评估1973‐2012年间肝内和肝外胆管癌年龄标化发病率的长期变化趋势 (根据系统编码误差校正) 。由于肝内胆管癌 (ICC) 常可能被误诊为原发部位不明的癌症 (CUP), 我们还对 CUP 发病率的变化趋势进行了分析。 结果. 1973‐2012 年间, 美国 ICC 发病率从 0.44/10 万人增长到 1.18/10 万人, 相当于年变化率 (APC) 为 2.30%。这一趋势在过去十年间进一步加剧, APC 提高至 4.36%。肝外胆管癌在 40 年间从 0.95/10 万人略增加到 1.02/10 万人 (APC: 0.14%)。 1973‐2012 年间, 组织学特征可能与胆管癌一致的 CUP 发病率下降了 51% (APC: ‐1.87%), 而鳞癌或非上皮性组织学特征的 CUP 的发病率则略有升高 (APC: 0.42%)。 结论. 在美国, 确诊的ICC发病率持续升高, 而ECC发病率保持稳定。而相同时期的CUP发病率则呈现大幅下降。The Oncologist 2016;21:594–599 对临床实践的提示: 对胆管癌[尤其是肝内胆管癌 (ICC) ]与原发部位不明的癌症 (CUP) 进行临床鉴别富有挑战性。 ICC 中近期识别出来的的复发和潜在靶位基因组异常强调了改进诊断的重要性。本研究证实美国的 ICC 发病率在持续升高, 而肝外胆管癌的发病率保持稳定。同一时期, CUP 的发病率则大幅下降, 提示 ICC 与 CUP 鉴别的进步可能是确诊的 ICC 发病率升高的主要驱动因素。 ICC 持续升高的发病率提示有必要针对其预防和治疗手段开展进一步的研究。 The recognized incidence of intrahepatic cholangiocarcinoma in the U.S. continues to rise, whereas the incidence of extrahepatic cholangiocarcinoma is stable. The incidence of carcinoma of unknown primary has fallen dramatically during the same time period. Challenges in the diagnosis and classification of cholangiocarcinoma have made it difficult to quantify the true incidence of this highly aggressive malignancy. We analyzed the Surveillance, Epidemiology, and End Results data to assess long-term trends in the age-standardized incidence of intrahepatic and extrahepatic cholangiocarcinoma between 1973 and 2012, correcting for systematic coding errors. Because intrahepatic cholangiocarcinoma (ICC) may frequently be misdiagnosed as cancer of unknown primary (CUP), we also analyzed trends in the incidence of CUP. Between 1973 and 2012, the reported U.S. incidence of ICC increased from 0.44 to 1.18 cases per 100,000, representing an annual percentage change (APC) of 2.30%; this trend has accelerated during the past decade to an APC of 4.36%. The incidence of extrahepatic cholangiocarcinoma increased modestly from 0.95 to 1.02 per 100,000 during the 40-year period (APC, 0.14%). The incidence of CUP with histologic features potentially consistent with cholangiocarcinoma decreased by 51% between 1973 and 2012 (APC, -1.87%), whereas the incidence of CUP with squamous or nonepithelial histologic features increased modestly (APC, 0.42%). The recognized incidence of ICC in the U.S. continues to rise, whereas the incidence of ECC is stable. The incidence of CUP has fallen dramatically during the same time period. Clinical distinctions between cholangiocarcinoma (particularly intrahepatic cholangiocarcinoma [ICC]) and cancer of unknown primary (CUP) can be challenging. Recent discoveries have identified recurrent and potentially targetable genomic abnormalities in ICC, highlighting the importance of improving diagnosis. This study demonstrates that the incidence of ICC is increasing in the U.S., whereas the incidence of extrahepatic cholangiocarcinoma is stable. Concomitantly, the incidence of CUP has declined dramatically, suggesting that improved distinction between ICC and CUP may be a major driver of the increasing recognized incidence of ICC. The increasing incidence of ICC warrants further study of prevention and treatment approaches. The recognized incidence of intrahepatic cholangiocarcinoma in the U.S. continues to rise, whereas the incidence of extrahepatic cholangiocarcinoma is stable. The incidence of carcinoma of unknown primary has fallen dramatically during the same time period. |
| Author | Zhu, Andrew X. Fuchs, Charles S. Brooks, Gabriel A. Saha, Supriya K. |
| Author_xml | – sequence: 1 givenname: Supriya K. surname: Saha fullname: Saha, Supriya K. – sequence: 2 givenname: Andrew X. surname: Zhu fullname: Zhu, Andrew X. – sequence: 3 givenname: Charles S. surname: Fuchs fullname: Fuchs, Charles S. – sequence: 4 givenname: Gabriel A. surname: Brooks fullname: Brooks, Gabriel A. email: gabriel_brooks@dfci.harvard.edu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27000463$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUUtuFDEUtKKg_OAKoZdserDbv3akIEUTApEiRoJEIivLsV_PGPXYE7sHNDuOwBk5CW5NiAirrPx5VfVKVYdoN8QACL0meEIEZW-HBcRgYx_nPg-TBhNeY8bEDjognKmaKfx1t9xxS2tJuNpHhzl_wwWmaLOH9huJMWaCHiBzEdOw-f3z1y2YVF0nCC5XPlTTRexNmPtoTbI-xKWpLoP1DoKFcV4MVDeTL5OT8j0ks4CVGbytzn0Gk6GKW8Tn8nyJXnSmz_Dq4TxCNxfvr6cf66vZh8vp2VVtOZWs5o0zUjXSOiLMnSPgmGNt01rJOFglHJUWsFBGUjBKdlxyYTvOMOlsxxymR-jdVne1vluCszD66vUq-aVJGx2N108nwS_0PH7XrBWEClEE3jwIpHi_hjzopc8W-pIDxHXWRLZt0wjSkgI9_nfX45K_uRaA3AJsijkn6B4hBOuxQf2kQT02qMcGC_P0P6b1Q8k2jqZ9_3z-D9_D5rlr9ezTdIa5YvQPtmK-mg |
| CitedBy_id | crossref_primary_10_1002_ame2_12370 crossref_primary_10_2217_fon_2017_0597 crossref_primary_10_3389_fonc_2021_711061 crossref_primary_10_1080_17474124_2021_1853527 crossref_primary_10_3389_fonc_2022_933943 crossref_primary_10_1016_j_bulcan_2019_12_004 crossref_primary_10_1016_j_neo_2024_101024 crossref_primary_10_3390_cancers14092137 crossref_primary_10_1007_s13304_020_00750_5 crossref_primary_10_2147_CMAR_S489960 crossref_primary_10_2147_CMAR_S317954 crossref_primary_10_2217_fon_2023_0098 crossref_primary_10_1177_10732748211009945 crossref_primary_10_1159_000453013 crossref_primary_10_5334_aogh_3660 crossref_primary_10_2217_pgs_2017_0010 crossref_primary_10_3389_fonc_2020_00525 crossref_primary_10_1038_s41392_024_02072_z crossref_primary_10_1002_hep_32771 crossref_primary_10_1001_jamaoncol_2021_3836 crossref_primary_10_1016_j_cpsurg_2020_100854 crossref_primary_10_1016_j_humpath_2022_06_020 crossref_primary_10_3390_cancers16152720 crossref_primary_10_3390_cancers16081537 crossref_primary_10_1016_j_bpg_2016_11_001 crossref_primary_10_1055_s_0044_1789612 crossref_primary_10_3390_curroncol28050293 crossref_primary_10_1111_his_13633 crossref_primary_10_1007_s11864_019_0655_0 crossref_primary_10_1067_j_cpradiol_2017_12_005 crossref_primary_10_1016_j_tige_2022_01_008 crossref_primary_10_1016_j_hpb_2021_03_007 crossref_primary_10_4240_wjgs_v16_i2_289 crossref_primary_10_4254_wjh_v16_i11_1282 crossref_primary_10_4174_astr_2022_102_5_248 crossref_primary_10_1016_j_gtc_2018_01_002 crossref_primary_10_1016_j_clnu_2021_04_038 crossref_primary_10_3892_mmr_2022_12687 crossref_primary_10_12677_acm_2024_1482384 crossref_primary_10_3390_ijms23010213 crossref_primary_10_1002_hep_31200 crossref_primary_10_3389_fonc_2022_860453 crossref_primary_10_1080_17474124_2022_2047651 crossref_primary_10_1016_j_ejrad_2021_109631 crossref_primary_10_1093_jnci_djad046 crossref_primary_10_3892_mmr_2018_8594 crossref_primary_10_1053_j_sult_2021_04_001 crossref_primary_10_1016_j_ajpath_2024_07_023 crossref_primary_10_1158_1078_0432_CCR_24_0657 crossref_primary_10_1038_s41467_024_44795_1 crossref_primary_10_1186_s40644_020_00323_0 crossref_primary_10_14701_ahbps_2020_24_2_182 crossref_primary_10_1016_S0140_6736_21_00153_7 crossref_primary_10_1002_cncr_32463 crossref_primary_10_6004_jnccn_2019_7304 crossref_primary_10_1097_TP_0000000000003539 crossref_primary_10_1186_s13046_018_0777_4 crossref_primary_10_1016_j_ejso_2023_05_014 crossref_primary_10_3390_cancers14133093 crossref_primary_10_1177_17588359211039047 crossref_primary_10_1016_j_celrep_2017_02_033 crossref_primary_10_1080_00365521_2022_2067785 crossref_primary_10_3389_fphar_2019_01238 crossref_primary_10_1007_s11938_021_00333_2 crossref_primary_10_1371_journal_pone_0265069 crossref_primary_10_1016_j_hpb_2023_01_011 crossref_primary_10_2147_CMAR_S357000 crossref_primary_10_1002_jhbp_12103 crossref_primary_10_1186_s12929_019_0599_5 crossref_primary_10_1016_j_canlet_2025_217540 crossref_primary_10_1093_jpp_rgab036 crossref_primary_10_1097_IPC_0000000000000659 crossref_primary_10_1186_s13046_024_03210_9 crossref_primary_10_1155_2020_3740418 crossref_primary_10_1038_s41419_023_06092_5 crossref_primary_10_1245_s10434_023_13872_y crossref_primary_10_2147_CMAR_S346235 crossref_primary_10_1016_j_soc_2019_06_007 crossref_primary_10_7759_cureus_55914 crossref_primary_10_1097_FTD_0000000000001119 crossref_primary_10_1007_s11605_019_04109_z crossref_primary_10_1111_ajt_16906 crossref_primary_10_1016_j_gene_2019_02_044 crossref_primary_10_1016_j_jvir_2024_08_006 crossref_primary_10_15279_kpba_2021_26_1_33 crossref_primary_10_3748_wjg_v29_i17_2642 crossref_primary_10_1007_s12328_021_01458_8 crossref_primary_10_1080_13543784_2018_1512581 crossref_primary_10_18632_aging_102747 crossref_primary_10_3390_genes14051104 crossref_primary_10_3892_etm_2023_12231 crossref_primary_10_1007_s00432_023_04875_z crossref_primary_10_2147_JIR_S311084 crossref_primary_10_3389_fonc_2019_00420 crossref_primary_10_12677_ACM_2023_131121 crossref_primary_10_3389_fgene_2020_522125 crossref_primary_10_3390_jcm10112368 crossref_primary_10_1007_s12029_020_00526_5 crossref_primary_10_1016_j_wfumbo_2024_100034 crossref_primary_10_3390_curroncol29070402 crossref_primary_10_1158_1940_6207_CAPR_21_0189 crossref_primary_10_1097_TP_0000000000003212 crossref_primary_10_1007_s00261_025_04856_5 crossref_primary_10_1007_s11523_022_00942_6 crossref_primary_10_3389_fonc_2020_576901 crossref_primary_10_1080_14728222_2021_1882998 crossref_primary_10_4143_crt_2023_726 crossref_primary_10_23873_2074_0506_2019_11_3_218_233 crossref_primary_10_3390_biomedicines10051022 crossref_primary_10_1007_s00432_024_05795_2 crossref_primary_10_1177_1533033820979703 crossref_primary_10_1007_s11901_019_00496_8 crossref_primary_10_3390_cancers12113157 crossref_primary_10_1080_14728222_2022_2029412 crossref_primary_10_1038_nrclinonc_2017_157 crossref_primary_10_1159_000454763 crossref_primary_10_1080_17474124_2021_1864325 crossref_primary_10_1038_s41467_024_47195_7 crossref_primary_10_1016_j_jhep_2018_09_014 crossref_primary_10_1016_j_soc_2019_06_012 crossref_primary_10_1002_hep_30289 crossref_primary_10_1038_s41419_019_1506_4 crossref_primary_10_1016_j_ejso_2023_107064 crossref_primary_10_4251_wjgo_v16_i4_1374 crossref_primary_10_1007_s10620_021_06973_9 crossref_primary_10_1186_s12967_022_03424_5 crossref_primary_10_4329_wjr_v16_i10_512 crossref_primary_10_5946_ce_2017_113 crossref_primary_10_1016_j_hbpd_2022_05_004 crossref_primary_10_1245_s10434_024_15724_9 crossref_primary_10_1016_S2468_1253_21_00171_0 crossref_primary_10_2217_hep_2017_0005 crossref_primary_10_1016_j_gastha_2021_12_003 crossref_primary_10_1007_s11901_023_00607_6 crossref_primary_10_31083_j_fbl2806120 crossref_primary_10_1177_10668969231157775 crossref_primary_10_1016_j_ejca_2019_05_030 crossref_primary_10_3390_microorganisms11102598 crossref_primary_10_18632_oncotarget_16330 crossref_primary_10_1007_s11523_023_01024_x crossref_primary_10_3748_wjg_v28_i28_3695 crossref_primary_10_4103_sjg_SJG_429_18 crossref_primary_10_3390_cancers15143638 crossref_primary_10_1097_HEP_0000000000000544 crossref_primary_10_1097_MOG_0000000000000611 crossref_primary_10_1080_13543784_2021_1900821 crossref_primary_10_1016_j_ijsu_2020_04_067 crossref_primary_10_1111_liv_14314 crossref_primary_10_1016_j_jss_2019_04_023 crossref_primary_10_5582_bst_2020_03240 crossref_primary_10_1016_j_ejso_2020_01_028 crossref_primary_10_1016_j_annonc_2022_10_506 crossref_primary_10_1186_s12885_020_06781_w crossref_primary_10_5009_gnl210346 crossref_primary_10_3390_jpm11121270 crossref_primary_10_70352_scrj_cr_24_0025 crossref_primary_10_1016_j_hpb_2024_03_1163 crossref_primary_10_3390_photonics9020065 crossref_primary_10_3390_cancers12092495 crossref_primary_10_5306_wjco_v13_i2_125 crossref_primary_10_1097_MD_0000000000035348 crossref_primary_10_1016_j_ajpath_2019_01_018 crossref_primary_10_1002_tox_23422 crossref_primary_10_1186_s12885_021_08947_6 crossref_primary_10_1016_j_ejso_2020_01_016 crossref_primary_10_1016_j_acra_2020_01_026 crossref_primary_10_1177_10732748211051548 crossref_primary_10_1002_ijc_34716 crossref_primary_10_1080_00365521_2022_2113426 crossref_primary_10_1007_s00259_019_04558_3 crossref_primary_10_1186_s13578_023_01156_7 crossref_primary_10_2147_CMAR_S276104 crossref_primary_10_1002_hep_32258 crossref_primary_10_1038_s41395_018_0207_4 crossref_primary_10_1016_j_soc_2020_08_005 crossref_primary_10_3390_biology11081098 crossref_primary_10_3390_cancers14071709 crossref_primary_10_1097_HEP_0000000000000760 crossref_primary_10_1634_theoncologist_2017_0439 crossref_primary_10_1016_j_clinre_2022_101955 crossref_primary_10_1002_cam4_6532 crossref_primary_10_1080_13543784_2021_1854724 crossref_primary_10_3390_cancers14205080 crossref_primary_10_1177_1758835919861914 crossref_primary_10_2147_OTT_S245575 crossref_primary_10_3390_medicines7090054 crossref_primary_10_1038_s41575_020_0310_z crossref_primary_10_4251_wjgo_v13_i10_1336 crossref_primary_10_70352_scrj_cr_24_0048 crossref_primary_10_1200_JOP_18_00558 crossref_primary_10_18632_oncotarget_17793 crossref_primary_10_1080_17474124_2021_1984879 crossref_primary_10_1016_j_mayocp_2024_10_021 crossref_primary_10_1186_s12935_021_02355_3 crossref_primary_10_1177_1073274817729241 crossref_primary_10_1111_cas_14677 crossref_primary_10_3390_diagnostics13020233 crossref_primary_10_24835_1607_0763_2018_5_55_64 crossref_primary_10_3748_wjg_v28_i15_1508 crossref_primary_10_1002_cam4_70135 crossref_primary_10_18632_oncotarget_14079 crossref_primary_10_3390_jpm11030233 crossref_primary_10_1007_s11605_018_3899_2 crossref_primary_10_1016_j_esmoop_2021_100275 crossref_primary_10_1097_MD_0000000000025635 crossref_primary_10_1038_s41419_019_1389_4 crossref_primary_10_1177_1073274820983013 crossref_primary_10_3390_cancers15113047 crossref_primary_10_1016_j_procbio_2021_01_017 crossref_primary_10_1080_14737167_2021_1842201 crossref_primary_10_4251_wjgo_v16_i4_1344 crossref_primary_10_1016_j_ejrad_2022_110603 crossref_primary_10_1155_2019_4304817 crossref_primary_10_4254_wjh_v13_i2_166 crossref_primary_10_1111_petr_13653 crossref_primary_10_1016_j_ctrv_2019_06_003 crossref_primary_10_1016_j_transproceed_2020_02_095 crossref_primary_10_1016_j_canep_2024_102721 crossref_primary_10_2147_CMAR_S276393 crossref_primary_10_3390_cancers13225709 crossref_primary_10_4291_wjgp_v12_i5_84 crossref_primary_10_3390_cancers15153993 crossref_primary_10_1016_j_cbi_2023_110816 crossref_primary_10_18632_aging_205759 crossref_primary_10_1007_s11912_017_0603_8 crossref_primary_10_1007_s12072_023_10487_z crossref_primary_10_1016_j_ejso_2018_09_008 crossref_primary_10_1016_j_aohep_2019_07_004 crossref_primary_10_1186_s13046_022_02549_1 crossref_primary_10_1016_j_heliyon_2024_e32113 crossref_primary_10_3390_cancers14235969 crossref_primary_10_25259_JCIS_59_2023 crossref_primary_10_1038_s41416_020_0835_5 crossref_primary_10_1172_jci_insight_174220 crossref_primary_10_1056_NEJMoa2206834 crossref_primary_10_1200_JCO_23_01566 crossref_primary_10_1002_hep_31094 crossref_primary_10_3389_fcimb_2021_751795 crossref_primary_10_1002_onco_13552 crossref_primary_10_3390_cancers16020297 crossref_primary_10_1038_s41416_022_01824_4 crossref_primary_10_1016_j_bbrc_2018_03_152 crossref_primary_10_3390_ijms21030825 crossref_primary_10_3390_cancers15092655 crossref_primary_10_1002_ags3_12691 crossref_primary_10_1148_rg_2018180067 crossref_primary_10_3892_mco_2021_2314 crossref_primary_10_4166_kjg_2023_110 crossref_primary_10_3390_cancers14235853 crossref_primary_10_3389_fonc_2021_677678 crossref_primary_10_1186_s12885_022_10025_4 crossref_primary_10_1186_s12885_024_12375_7 crossref_primary_10_1055_a_1775_9024 crossref_primary_10_17925_OHR_2020_16_1_52 crossref_primary_10_3389_fonc_2023_1197626 crossref_primary_10_3390_cells11233929 crossref_primary_10_1016_j_suc_2023_07_006 crossref_primary_10_1002_ctm2_1502 crossref_primary_10_1188_18_CJON_E97_E102 crossref_primary_10_1016_j_hbpd_2020_02_005 crossref_primary_10_1159_000530134 crossref_primary_10_1007_s00018_024_05526_3 crossref_primary_10_2147_CMAR_S330710 crossref_primary_10_1016_j_jchirv_2023_04_017 crossref_primary_10_1080_13543784_2023_2173064 crossref_primary_10_1007_s11864_020_00767_3 crossref_primary_10_1007_s12029_022_00820_4 crossref_primary_10_1097_MD_0000000000017903 crossref_primary_10_20517_2394_5079_2023_60 crossref_primary_10_1245_s10434_024_16118_7 crossref_primary_10_1159_000520346 crossref_primary_10_1007_s00423_020_01955_3 crossref_primary_10_1080_17425255_2022_2039118 crossref_primary_10_1007_s00464_016_5399_3 crossref_primary_10_1016_j_intimp_2020_107069 crossref_primary_10_1080_00365521_2023_2277663 crossref_primary_10_1136_bcr_2017_223539 crossref_primary_10_1080_13543784_2021_1837774 crossref_primary_10_1186_s13046_023_02813_y crossref_primary_10_1200_PO_18_00414 crossref_primary_10_1080_17474124_2021_1890031 crossref_primary_10_3389_fmed_2024_1384314 crossref_primary_10_1002_ijc_33323 crossref_primary_10_1038_s41419_024_06839_8 crossref_primary_10_1177_0003134820952378 crossref_primary_10_7717_peerj_10464 crossref_primary_10_1080_14656566_2024_2406287 crossref_primary_10_1097_MD_0000000000015364 crossref_primary_10_1158_2159_8290_CD_15_1442 crossref_primary_10_1002_ijc_32230 crossref_primary_10_1016_j_pdpdt_2025_104472 crossref_primary_10_1186_s12876_022_02637_8 crossref_primary_10_1016_j_ctrv_2021_102258 crossref_primary_10_1371_journal_pone_0186643 crossref_primary_10_1007_s00261_017_1094_7 crossref_primary_10_1016_j_clinre_2021_101836 crossref_primary_10_1016_j_gassur_2025_101968 crossref_primary_10_1186_s12885_021_09070_2 crossref_primary_10_1111_pin_12983 crossref_primary_10_1007_s00261_023_03890_5 crossref_primary_10_1155_2022_3970884 crossref_primary_10_1016_j_bbadis_2017_07_027 crossref_primary_10_1007_s00464_019_06871_2 crossref_primary_10_1097_MD_0000000000020932 crossref_primary_10_1002_cncr_32803 crossref_primary_10_1186_s12885_017_3967_0 crossref_primary_10_1016_j_suc_2023_09_004 crossref_primary_10_1016_j_annonc_2021_04_012 crossref_primary_10_18632_oncotarget_23807 crossref_primary_10_3390_cancers13205074 crossref_primary_10_1186_s12885_025_13814_9 crossref_primary_10_3389_fmicb_2022_1090392 crossref_primary_10_1001_jamanetworkopen_2023_51502 crossref_primary_10_3390_cancers13153657 crossref_primary_10_3390_curroncol30030201 crossref_primary_10_1007_s10552_024_01955_4 crossref_primary_10_1097_HEP_0000000000001200 crossref_primary_10_3390_jpm12040540 crossref_primary_10_1016_j_cytogfr_2019_12_005 crossref_primary_10_3390_cells12030370 crossref_primary_10_1016_j_heliyon_2024_e27366 crossref_primary_10_1016_j_trecan_2021_01_012 crossref_primary_10_1016_j_jhepr_2021_100226 crossref_primary_10_1002_cncr_31942 crossref_primary_10_3892_etm_2022_11483 crossref_primary_10_1007_s40487_021_00159_z crossref_primary_10_2147_CMAR_S254955 crossref_primary_10_2217_fon_2023_0318 crossref_primary_10_1016_j_colsurfb_2020_111005 crossref_primary_10_1177_17588359211036544 crossref_primary_10_1097_MEG_0000000000001337 crossref_primary_10_5582_bst_2024_01277 crossref_primary_10_1159_000517533 crossref_primary_10_1016_j_jdcr_2017_01_024 crossref_primary_10_1016_j_currproblcancer_2018_01_015 crossref_primary_10_5009_gnl220477 crossref_primary_10_3389_fonc_2020_00171 crossref_primary_10_1016_j_jhep_2021_12_010 crossref_primary_10_1097_MEG_0000000000002313 crossref_primary_10_1016_j_hpb_2018_08_004 crossref_primary_10_1016_j_livres_2024_11_005 crossref_primary_10_1038_s41598_018_25669_1 crossref_primary_10_1016_j_hpb_2019_11_008 crossref_primary_10_1038_s41598_022_13605_3 crossref_primary_10_2217_imt_2019_0100 crossref_primary_10_1016_j_med_2020_06_020 crossref_primary_10_1016_j_mayocp_2024_07_005 crossref_primary_10_1038_s41388_021_01705_9 crossref_primary_10_1038_s41416_020_0987_3 crossref_primary_10_1038_s41598_021_83149_5 crossref_primary_10_1016_j_jhepr_2022_100648 crossref_primary_10_1038_s41698_022_00320_5 crossref_primary_10_1155_2019_1092563 crossref_primary_10_1016_j_ajpath_2024_10_021 crossref_primary_10_1080_17474124_2022_2017772 crossref_primary_10_2147_CMAR_S326060 crossref_primary_10_2147_CMAR_S478477 crossref_primary_10_2147_OTT_S257738 crossref_primary_10_1080_14740338_2024_2446405 crossref_primary_10_1371_journal_pone_0260180 crossref_primary_10_1055_s_0045_1805052 crossref_primary_10_1016_j_cmpb_2021_106265 crossref_primary_10_1016_S0140_6736_23_00767_5 crossref_primary_10_1158_2159_8290_CD_16_1000 crossref_primary_10_1055_s_0042_1751238 crossref_primary_10_3389_fonc_2021_704042 crossref_primary_10_3892_mco_2021_2485 crossref_primary_10_1080_13102818_2022_2118076 crossref_primary_10_1007_s11901_018_0426_6 crossref_primary_10_1002_cncr_31872 crossref_primary_10_1016_j_asjsur_2021_06_031 crossref_primary_10_1007_s00535_020_01714_7 crossref_primary_10_1016_j_prmcm_2024_100505 crossref_primary_10_1007_s11605_017_3499_6 crossref_primary_10_1093_jjco_hyab029 crossref_primary_10_1016_j_anndiagpath_2025_152437 crossref_primary_10_1155_2020_5846938 crossref_primary_10_1038_s41419_022_05247_0 crossref_primary_10_1016_S1470_2045_19_30733_8 crossref_primary_10_4254_wjh_v12_i11_897 crossref_primary_10_1002_cncr_33803 crossref_primary_10_3389_fonc_2024_1428370 crossref_primary_10_3389_fphar_2021_650388 crossref_primary_10_1056_NEJMcpc2027092 crossref_primary_10_3389_fonc_2020_00143 crossref_primary_10_1093_oncolo_oyac150 crossref_primary_10_3389_fonc_2023_1227036 crossref_primary_10_4240_wjgs_v14_i1_1 crossref_primary_10_1186_s12885_022_10373_1 crossref_primary_10_1016_j_esmoop_2022_100505 crossref_primary_10_1186_s12957_021_02426_9 crossref_primary_10_1097_MEG_0000000000002503 crossref_primary_10_3390_diagnostics13091542 crossref_primary_10_1002_jcb_29222 crossref_primary_10_1080_23808993_2021_1915126 crossref_primary_10_1093_oncolo_oyac139 crossref_primary_10_3892_mmr_2019_10730 crossref_primary_10_1002_hep_31817 crossref_primary_10_1016_j_trre_2019_100516 crossref_primary_10_3389_fnut_2022_964591 crossref_primary_10_1007_s13304_020_00930_3 crossref_primary_10_4103_pm_pm_288_19 crossref_primary_10_1038_s41598_024_52025_3 crossref_primary_10_1186_s12885_019_6142_y crossref_primary_10_1001_jamaoncol_2019_3691 crossref_primary_10_1016_j_hpb_2023_12_004 crossref_primary_10_1158_1535_7163_MCT_21_0015 crossref_primary_10_1186_s12885_020_07357_4 crossref_primary_10_2217_fon_2018_0846 crossref_primary_10_1016_j_jviscsurg_2023_07_007 crossref_primary_10_1158_2159_8290_CD_20_0766 crossref_primary_10_1007_s12029_024_01113_8 crossref_primary_10_1097_COC_0000000000001108 crossref_primary_10_1016_j_suc_2018_12_004 crossref_primary_10_1002_hep_31829 crossref_primary_10_1002_cam4_6063 crossref_primary_10_1007_s11605_020_04721_4 crossref_primary_10_1002_ueg2_12154 crossref_primary_10_1016_j_aohep_2024_101773 crossref_primary_10_1186_s12876_016_0527_z crossref_primary_10_3389_fcell_2023_1182900 crossref_primary_10_1186_s12885_024_12929_9 crossref_primary_10_1111_cas_16140 crossref_primary_10_2214_AJR_22_27783 crossref_primary_10_1038_s41572_021_00300_2 crossref_primary_10_1016_j_ejca_2022_08_032 crossref_primary_10_1001_jamaoncol_2019_3718 crossref_primary_10_3389_fonc_2023_1203685 crossref_primary_10_1016_j_hpb_2020_07_007 crossref_primary_10_4251_wjgo_v15_i6_959 crossref_primary_10_1634_theoncologist_2018_0044 crossref_primary_10_1016_j_phrs_2023_106706 crossref_primary_10_1016_j_hpb_2023_02_016 crossref_primary_10_1080_13543784_2021_1880565 crossref_primary_10_1186_s12935_020_01687_w crossref_primary_10_1016_j_gie_2020_06_013 crossref_primary_10_1016_j_tranon_2019_05_020 crossref_primary_10_3389_fonc_2022_824541 crossref_primary_10_3390_curroncol32020087 crossref_primary_10_3390_cancers15082368 crossref_primary_10_1007_s00261_024_04410_9 crossref_primary_10_1016_j_hoc_2024_08_005 crossref_primary_10_20935_AcadOnco7553 crossref_primary_10_1016_j_hpb_2022_03_007 crossref_primary_10_1016_j_ctarc_2021_100354 crossref_primary_10_1016_j_ctarc_2021_100356 crossref_primary_10_1111_liv_14095 crossref_primary_10_1007_s00259_022_05765_1 crossref_primary_10_1038_s41598_025_85241_6 crossref_primary_10_1016_j_canlet_2019_11_036 crossref_primary_10_1111_apt_18473 crossref_primary_10_2217_fon_2020_0299 crossref_primary_10_3390_medicina59071186 crossref_primary_10_37174_2587_7593_2021_4_1_74_93 crossref_primary_10_1016_j_mtbio_2025_101581 crossref_primary_10_3390_biology12070999 crossref_primary_10_1186_s12885_022_10286_z crossref_primary_10_1016_j_sipas_2021_100028 crossref_primary_10_1016_j_annonc_2022_09_150 crossref_primary_10_1093_jnci_djy171 crossref_primary_10_3892_ol_2021_13157 crossref_primary_10_1016_j_jhep_2019_09_007 crossref_primary_10_1016_j_ctarc_2021_100337 crossref_primary_10_1016_j_ctarc_2021_100334 crossref_primary_10_1016_j_ctarc_2021_100335 crossref_primary_10_1002_jcla_24694 crossref_primary_10_1007_s40472_021_00313_6 crossref_primary_10_1016_j_ejca_2022_11_006 crossref_primary_10_1155_2020_5976127 crossref_primary_10_1002_lci2_43 crossref_primary_10_4251_wjgo_v15_i6_1036 crossref_primary_10_3390_diagnostics13081488 crossref_primary_10_1002_jso_25485 crossref_primary_10_12677_ACM_2021_1112886 crossref_primary_10_1186_s43556_024_00184_0 crossref_primary_10_2217_fon_2021_1089 crossref_primary_10_3892_ol_2019_10904 crossref_primary_10_1097_CM9_0000000000003258 crossref_primary_10_4103_ijc_IJC_622_17 crossref_primary_10_1200_PO_22_00594 crossref_primary_10_1016_j_amjsurg_2021_03_052 crossref_primary_10_1080_08941939_2019_1604916 crossref_primary_10_12998_wjcc_v10_i3_790 crossref_primary_10_3390_jcm12041268 crossref_primary_10_1016_j_clinre_2020_03_024 crossref_primary_10_1016_j_ultrasmedbio_2024_09_009 crossref_primary_10_3389_fcell_2022_890605 crossref_primary_10_1016_j_ctrv_2021_102170 crossref_primary_10_1080_17474124_2021_1974294 crossref_primary_10_1080_17474124_2021_1974296 crossref_primary_10_1177_0300060521989200 crossref_primary_10_1245_s10434_019_08142_9 crossref_primary_10_3389_fsurg_2023_1002411 crossref_primary_10_3390_cancers12113310 crossref_primary_10_1245_s10434_022_12058_2 crossref_primary_10_1016_j_jnutbio_2019_108245 crossref_primary_10_1002_jmri_29477 crossref_primary_10_1177_15330338241239139 crossref_primary_10_1002_lsm_23857 crossref_primary_10_1590_s0004_2803_23032023_107 crossref_primary_10_1245_s10434_023_14255_z crossref_primary_10_1016_j_hpb_2019_06_007 crossref_primary_10_1080_17474124_2021_1911646 crossref_primary_10_1245_s10434_023_14254_0 crossref_primary_10_3390_cancers13236049 crossref_primary_10_3390_cancers15225373 crossref_primary_10_3390_jcm9072255 crossref_primary_10_1002_jhbp_916 crossref_primary_10_1371_journal_pone_0306060 crossref_primary_10_1016_j_ctrv_2024_102851 crossref_primary_10_1245_s10434_023_13349_y |
| Cites_doi | 10.1186/1471-2407-2-10 10.1093/jnci/djj234 10.1016/S0140-6736(05)67530-7 10.1053/j.gastro.2009.02.038 10.1016/j.humpath.2012.11.006 10.1155/2013/196412 10.1634/theoncologist.2011-0386 10.1007/s10620-014-3276-2 10.1038/onc.2012.315 10.1200/JCO.2012.43.3755 10.1016/j.humpath.2014.03.014 10.1053/jhep.2001.25087 10.1038/ncomms7087 10.1245/s10434-014-3828-x 10.1136/gut.48.6.816 10.1245/s10434-014-4247-8 10.1136/gutjnl-2011-301748 10.1056/NEJMra1303917 10.1002/hep.26890 10.1038/ng.2813 10.1016/j.jhep.2003.11.030 10.1038/nrgastro.2011.131 10.1634/theoncologist.2013-0352 10.1038/ng.2806 10.1016/j.jhep.2011.11.015 10.1016/j.jhep.2014.01.021 10.1007/978-1-4757-3656-4 10.18632/oncotarget.1943 10.1016/j.jhep.2012.02.022 10.1111/j.1478-3231.2006.01350.x |
| ContentType | Journal Article |
| Copyright | 2016 AlphaMed Press AlphaMed Press. AlphaMed Press 2016 |
| Copyright_xml | – notice: 2016 AlphaMed Press – notice: AlphaMed Press. – notice: AlphaMed Press 2016 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1634/theoncologist.2015-0446 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Long-Term Trends in Cholangiocarcinoma Incidence |
| EISSN | 1549-490X |
| EndPage | 599 |
| ExternalDocumentID | PMC4861366 27000463 10_1634_theoncologist_2015_0446 ONCO0594 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: Robert T. and Judith B. Hale Fund for Pancreatic Cancer Research – fundername: National Institutes of Health funderid: R25CA09220 – fundername: National Institutes of Health funderid: 5P50CA127003; 5R01CA124908 – fundername: DF/HCC GI SPORE Career Development Project Award funderid: P50CA127003 – fundername: National Cancer Institute Mentored Clinical Scientist Research Career Development Award funderid: 1K08CA194268‐01 – fundername: V Foundation for Cancer Research – fundername: Lustgarten Foundation for Pancreatic Cancer Research – fundername: National Cancer Institute – fundername: NCI NIH HHS grantid: R25 CA092203 – fundername: NCI NIH HHS grantid: P50 CA127003 – fundername: NCI NIH HHS grantid: R01 CA124908 – fundername: NCI NIH HHS grantid: K08 CA194268 |
| GroupedDBID | --- 0R~ 123 18M 1OC 24P 2WC 36B 4.4 53G 5VS AAPXW AAVAP AAWTL AAZKR ABEJV ABPTD ABXVV ACXQS ADBBV ADXAS AEGXH AENEX AJAOE ALMA_UNASSIGNED_HOLDINGS AMNDL AOIJS BAWUL BFHJK CS3 DCZOG DIK DU5 E3Z EBD EBS EJD EMB EMOBN F5P FRP GROUPED_DOAJ GX1 H13 HYE HZ~ IAO IHR INH ITC LUTES LYRES O9- OK1 P2P P2W RAO RHF RHI ROL ROX RPM SUPJJ SV3 TOX TR2 UDS W2D W8F WIN WOHZO WOQ WOW XSB ZZTAW AAFWJ AAYXX ABGNP AFPKN CITATION OVT CGR CUY CVF ECM EIF NPM 7X8 AAMMB AEFGJ AGXDD AIDQK AIDYY 5PM |
| ID | FETCH-LOGICAL-c5374-52da7927cd16abd1ed4d4828c745ec96d37ce069a73ea97f5756cf5401fcf4d03 |
| ISSN | 1083-7159 1549-490X |
| IngestDate | Thu Aug 21 14:12:38 EDT 2025 Fri Jul 11 00:14:10 EDT 2025 Wed Feb 19 01:55:55 EST 2025 Tue Jul 01 00:48:18 EDT 2025 Thu Apr 24 22:57:29 EDT 2025 Wed Jan 22 16:21:20 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Trend Extrahepatic cholangiocarcinoma Cancer of unknown primary Epidemiology Intrahepatic cholangiocarcinoma Incidence |
| Language | English |
| License | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model AlphaMed Press. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c5374-52da7927cd16abd1ed4d4828c745ec96d37ce069a73ea97f5756cf5401fcf4d03 |
| Notes | Disclosures of potential conflicts of interest may be found at the end of this article. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC4861366 |
| PMID | 27000463 |
| PQID | 1788226181 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4861366 proquest_miscellaneous_1788226181 pubmed_primary_27000463 crossref_primary_10_1634_theoncologist_2015_0446 crossref_citationtrail_10_1634_theoncologist_2015_0446 wiley_primary_10_1634_theoncologist_2015_0446_ONCO0594 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | May 2016 |
| PublicationDateYYYYMMDD | 2016-05-01 |
| PublicationDate_xml | – month: 05 year: 2016 text: May 2016 |
| PublicationDecade | 2010 |
| PublicationPlace | Durham, NC, USA |
| PublicationPlace_xml | – name: Durham, NC, USA – name: United States |
| PublicationTitle | The oncologist (Dayton, Ohio) |
| PublicationTitleAlternate | Oncologist |
| PublicationYear | 2016 |
| Publisher | AlphaMed Press |
| Publisher_xml | – name: AlphaMed Press |
| References | 2012; 61 2015; 6 2004; 40 2013; 44 2006; 98 2013; 45 2002; 2 2001; 48 2014; 371 2012; 17 2002 2012; 57 2012; 56 2014; 60 2011; 8 2009; 136 2014; 45 2014; 21 2014; 5 2013; 32 2005; 366 2013; 34 2013; 31 2006; 26 2014; 59 2014; 19 2001; 33 2016; 23 Graham (2021122309580605200_B20) 2014; 45 2021122309580605200_B30 Simbolo (2021122309580605200_B24) 2014; 5 Khan (2021122309580605200_B1) 2012; 56 Palmer (2021122309580605200_B32) 2012; 57 Shaib (2021122309580605200_B5) 2004; 40 Hainsworth (2021122309580605200_B15) 2013; 31 Green (2021122309580605200_B31) 2002 Malaguarnera (2021122309580605200_B13) 2013; 34 Chan-On (2021122309580605200_B19) 2013; 45 Patel (2021122309580605200_B4) 2002; 2 Borger (2021122309580605200_B18) 2012; 17 2021122309580605200_B28 2021122309580605200_B29 Voss (2021122309580605200_B25) 2013; 44 Jiao (2021122309580605200_B21) 2013; 45 Ross (2021122309580605200_B22) 2014; 19 Arai (2021122309580605200_B17) 2014; 59 Everhart (2021122309580605200_B10) 2009; 136 Varadhachary (2021122309580605200_B14) 2014; 371 Bridgewater (2021122309580605200_B12) 2014; 60 Sia (2021122309580605200_B23) 2015; 6 Khan (2021122309580605200_B2) 2005; 366 McLean (2021122309580605200_B33) 2006; 26 Taylor-Robinson (2021122309580605200_B6) 2001; 48 Wang (2021122309580605200_B26) 2013; 32 Zhu (2021122309580605200_B27) 2014; 21 Blechacz (2021122309580605200_B9) 2011; 8 Khan (2021122309580605200_B11) 2012; 61 Welzel (2021122309580605200_B8) 2006; 98 Ferrone (2021122309580605200_B16) 2016; 23 Tyson (2021122309580605200_B7) 2014; 59 Patel (2021122309580605200_B3) 2001; 33 24185513 - Nat Genet. 2013 Dec;45(12):1474-8 21808282 - Nat Rev Gastroenterol Hepatol. 2011 Sep;8(9):512-22 24185509 - Nat Genet. 2013 Dec;45(12):1470-3 23391413 - Hum Pathol. 2013 Jul;44(7):1216-22 17032404 - Liver Int. 2006 Nov;26(9):1047-53 15123362 - J Hepatol. 2004 Mar;40(3):472-7 22180306 - Oncologist. 2012;17(1):72-9 25140961 - N Engl J Med. 2014 Aug 21;371(8):757-65 11991810 - BMC Cancer. 2002 May 3;2:10 23396291 - Dis Markers. 2013;34(4):219-28 24563076 - Oncologist. 2014 Mar;19(3):235-42 11358902 - Gut. 2001 Jun;48(6):816-20 16788161 - J Natl Cancer Inst. 2006 Jun 21;98(12):873-5 25204668 - Dig Dis Sci. 2014 Dec;59(12):3103-10 23032625 - J Clin Oncol. 2013 Jan 10;31(2):217-23 24889489 - Ann Surg Oncol. 2014 Nov;21(12):3827-34 22895392 - Gut. 2012 Dec;61(12):1657-69 22173164 - J Hepatol. 2012 Apr;56(4):848-54 24867389 - Oncotarget. 2014 May 15;5(9):2839-52 24681130 - J Hepatol. 2014 Jun;60(6):1268-89 19245868 - Gastroenterology. 2009 Apr;136(4):1134-44 24837095 - Hum Pathol. 2014 Aug;45(8):1630-8 22824796 - Oncogene. 2013 Jun 20;32(25):3091-100 22420979 - J Hepatol. 2012 Jul;57(1):69-76 25608663 - Nat Commun. 2015;6:6087 25519926 - Ann Surg Oncol. 2016 Jan;23(1):290-6 11391522 - Hepatology. 2001 Jun;33(6):1353-7 24122810 - Hepatology. 2014 Apr;59(4):1427-34 16214602 - Lancet. 2005 Oct 8;366(9493):1303-14 |
| References_xml | – volume: 8 start-page: 512 year: 2011 end-page: 522 article-title: Clinical diagnosis and staging of cholangiocarcinoma publication-title: Nat Rev Gastroenterol Hepatol – volume: 33 start-page: 1353 year: 2001 end-page: 1357 article-title: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States publication-title: Hepatology – volume: 45 start-page: 1630 year: 2014 end-page: 1638 article-title: Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma publication-title: Hum Pathol – volume: 31 start-page: 217 year: 2013 end-page: 223 article-title: Molecular gene expression profiling to predict the tissue of origin and direct site‐specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute publication-title: J Clin Oncol – volume: 44 start-page: 1216 year: 2013 end-page: 1222 article-title: Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions publication-title: Hum Pathol – volume: 32 start-page: 3091 year: 2013 end-page: 3100 article-title: Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas publication-title: Oncogene – volume: 17 start-page: 72 year: 2012 end-page: 79 article-title: Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad‐based tumor genotyping publication-title: The Oncologist – volume: 26 start-page: 1047 year: 2006 end-page: 1053 article-title: Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the united states publication-title: Liver Int – volume: 45 start-page: 1474 year: 2013 end-page: 1478 article-title: Exome sequencing identifies distinct mutational patterns in liver fluke‐related and non‐infection‐related bile duct cancers publication-title: Nat Genet – volume: 45 start-page: 1470 year: 2013 end-page: 1473 article-title: Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas publication-title: Nat Genet – volume: 19 start-page: 235 year: 2014 end-page: 242 article-title: New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next‐generation sequencing publication-title: The Oncologist – volume: 60 start-page: 1268 year: 2014 end-page: 1289 article-title: Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma publication-title: J Hepatol – volume: 6 start-page: 6087 year: 2015 article-title: Massive parallel sequencing uncovers actionable FGFR2‐PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma publication-title: Nat Commun – volume: 366 start-page: 1303 year: 2005 end-page: 1314 article-title: Cholangiocarcinoma publication-title: Lancet – volume: 48 start-page: 816 year: 2001 end-page: 820 article-title: Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968‐1998 publication-title: Gut – volume: 21 start-page: 3827 year: 2014 end-page: 3834 article-title: Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets publication-title: Ann Surg Oncol – volume: 5 start-page: 2839 year: 2014 end-page: 2852 article-title: Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups publication-title: Oncotarget – year: 2002 – volume: 61 start-page: 1657 year: 2012 end-page: 1669 article-title: Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update publication-title: Gut – volume: 371 start-page: 757 year: 2014 end-page: 765 article-title: Cancer of unknown primary site publication-title: N Engl J Med – volume: 57 start-page: 69 year: 2012 end-page: 76 article-title: Are common factors involved in the pathogenesis of primary liver cancers? A meta‐analysis of risk factors for intrahepatic cholangiocarcinoma publication-title: J Hepatol – volume: 136 start-page: 1134 year: 2009 end-page: 1144 article-title: Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas publication-title: Gastroenterology – volume: 23 start-page: 290 year: 2016 end-page: 296 article-title: The ability to diagnose intrahepatic cholangiocarcinoma definitively using novel branched DNA‐enhanced albumin rna in situ hybridization technology publication-title: Ann Surg Oncol – volume: 40 start-page: 472 year: 2004 end-page: 477 article-title: Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? publication-title: J Hepatol – volume: 59 start-page: 3103 year: 2014 end-page: 3110 article-title: Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification publication-title: Dig Dis Sci – volume: 98 start-page: 873 year: 2006 end-page: 875 article-title: Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra‐ and extrahepatic cholangiocarcinoma in the United States publication-title: J Natl Cancer Inst – volume: 2 start-page: 10 year: 2002 article-title: Worldwide trends in mortality from biliary tract malignancies publication-title: BMC Cancer – volume: 56 start-page: 848 year: 2012 end-page: 854 article-title: Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? publication-title: J Hepatol – volume: 59 start-page: 1427 year: 2014 end-page: 1434 article-title: Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma publication-title: Hepatology – volume: 34 start-page: 219 year: 2013 end-page: 228 article-title: Serum markers of intrahepatic cholangiocarcinoma publication-title: Dis Markers – volume: 2 start-page: 10 year: 2002 ident: 2021122309580605200_B4 article-title: Worldwide trends in mortality from biliary tract malignancies publication-title: BMC Cancer doi: 10.1186/1471-2407-2-10 – volume: 98 start-page: 873 year: 2006 ident: 2021122309580605200_B8 article-title: Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djj234 – volume: 366 start-page: 1303 year: 2005 ident: 2021122309580605200_B2 article-title: Cholangiocarcinoma publication-title: Lancet doi: 10.1016/S0140-6736(05)67530-7 – volume: 136 start-page: 1134 year: 2009 ident: 2021122309580605200_B10 article-title: Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas publication-title: Gastroenterology doi: 10.1053/j.gastro.2009.02.038 – volume: 44 start-page: 1216 year: 2013 ident: 2021122309580605200_B25 article-title: Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions publication-title: Hum Pathol doi: 10.1016/j.humpath.2012.11.006 – volume: 34 start-page: 219 year: 2013 ident: 2021122309580605200_B13 article-title: Serum markers of intrahepatic cholangiocarcinoma publication-title: Dis Markers doi: 10.1155/2013/196412 – volume: 17 start-page: 72 year: 2012 ident: 2021122309580605200_B18 article-title: Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping publication-title: The Oncologist doi: 10.1634/theoncologist.2011-0386 – volume: 59 start-page: 3103 year: 2014 ident: 2021122309580605200_B7 article-title: Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification publication-title: Dig Dis Sci doi: 10.1007/s10620-014-3276-2 – volume: 32 start-page: 3091 year: 2013 ident: 2021122309580605200_B26 article-title: Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas publication-title: Oncogene doi: 10.1038/onc.2012.315 – volume: 31 start-page: 217 year: 2013 ident: 2021122309580605200_B15 article-title: Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute publication-title: J Clin Oncol doi: 10.1200/JCO.2012.43.3755 – volume: 45 start-page: 1630 year: 2014 ident: 2021122309580605200_B20 article-title: Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma publication-title: Hum Pathol doi: 10.1016/j.humpath.2014.03.014 – volume: 33 start-page: 1353 year: 2001 ident: 2021122309580605200_B3 article-title: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States publication-title: Hepatology doi: 10.1053/jhep.2001.25087 – volume: 6 start-page: 6087 year: 2015 ident: 2021122309580605200_B23 article-title: Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma publication-title: Nat Commun doi: 10.1038/ncomms7087 – volume: 21 start-page: 3827 year: 2014 ident: 2021122309580605200_B27 article-title: Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets publication-title: Ann Surg Oncol doi: 10.1245/s10434-014-3828-x – volume: 48 start-page: 816 year: 2001 ident: 2021122309580605200_B6 article-title: Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998 publication-title: Gut doi: 10.1136/gut.48.6.816 – volume: 23 start-page: 290 year: 2016 ident: 2021122309580605200_B16 article-title: The ability to diagnose intrahepatic cholangiocarcinoma definitively using novel branched DNA-enhanced albumin rna in situ hybridization technology publication-title: Ann Surg Oncol doi: 10.1245/s10434-014-4247-8 – volume: 61 start-page: 1657 year: 2012 ident: 2021122309580605200_B11 article-title: Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update publication-title: Gut doi: 10.1136/gutjnl-2011-301748 – volume-title: National Cancer Institute. SEER*Stat trend algorithms ident: 2021122309580605200_B30 – volume: 371 start-page: 757 year: 2014 ident: 2021122309580605200_B14 article-title: Cancer of unknown primary site publication-title: N Engl J Med doi: 10.1056/NEJMra1303917 – volume: 59 start-page: 1427 year: 2014 ident: 2021122309580605200_B17 article-title: Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma publication-title: Hepatology doi: 10.1002/hep.26890 – volume: 45 start-page: 1470 year: 2013 ident: 2021122309580605200_B21 article-title: Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas publication-title: Nat Genet doi: 10.1038/ng.2813 – volume-title: National Cancer Institute. Surveillance, Epidemiology and End Results. Overview of the SEER program ident: 2021122309580605200_B28 – volume-title: National Cancer Institute. Surveillance Research Program, National Cancer Institute SEER*Stat software. Version 8.2.1 ident: 2021122309580605200_B29 – volume: 40 start-page: 472 year: 2004 ident: 2021122309580605200_B5 article-title: Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? publication-title: J Hepatol doi: 10.1016/j.jhep.2003.11.030 – volume: 8 start-page: 512 year: 2011 ident: 2021122309580605200_B9 article-title: Clinical diagnosis and staging of cholangiocarcinoma publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2011.131 – volume: 19 start-page: 235 year: 2014 ident: 2021122309580605200_B22 article-title: New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing publication-title: The Oncologist doi: 10.1634/theoncologist.2013-0352 – volume: 45 start-page: 1474 year: 2013 ident: 2021122309580605200_B19 article-title: Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers publication-title: Nat Genet doi: 10.1038/ng.2806 – volume: 56 start-page: 848 year: 2012 ident: 2021122309580605200_B1 article-title: Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? publication-title: J Hepatol doi: 10.1016/j.jhep.2011.11.015 – volume: 60 start-page: 1268 year: 2014 ident: 2021122309580605200_B12 article-title: Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2014.01.021 – volume-title: AJCC Cancer Staging Manual year: 2002 ident: 2021122309580605200_B31 doi: 10.1007/978-1-4757-3656-4 – volume: 5 start-page: 2839 year: 2014 ident: 2021122309580605200_B24 article-title: Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups publication-title: Oncotarget doi: 10.18632/oncotarget.1943 – volume: 57 start-page: 69 year: 2012 ident: 2021122309580605200_B32 article-title: Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2012.02.022 – volume: 26 start-page: 1047 year: 2006 ident: 2021122309580605200_B33 article-title: Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the united states publication-title: Liver Int doi: 10.1111/j.1478-3231.2006.01350.x – reference: 24563076 - Oncologist. 2014 Mar;19(3):235-42 – reference: 22895392 - Gut. 2012 Dec;61(12):1657-69 – reference: 23391413 - Hum Pathol. 2013 Jul;44(7):1216-22 – reference: 24185513 - Nat Genet. 2013 Dec;45(12):1474-8 – reference: 25204668 - Dig Dis Sci. 2014 Dec;59(12):3103-10 – reference: 16788161 - J Natl Cancer Inst. 2006 Jun 21;98(12):873-5 – reference: 22173164 - J Hepatol. 2012 Apr;56(4):848-54 – reference: 23396291 - Dis Markers. 2013;34(4):219-28 – reference: 19245868 - Gastroenterology. 2009 Apr;136(4):1134-44 – reference: 11358902 - Gut. 2001 Jun;48(6):816-20 – reference: 23032625 - J Clin Oncol. 2013 Jan 10;31(2):217-23 – reference: 25519926 - Ann Surg Oncol. 2016 Jan;23(1):290-6 – reference: 24837095 - Hum Pathol. 2014 Aug;45(8):1630-8 – reference: 11991810 - BMC Cancer. 2002 May 3;2:10 – reference: 17032404 - Liver Int. 2006 Nov;26(9):1047-53 – reference: 22180306 - Oncologist. 2012;17(1):72-9 – reference: 11391522 - Hepatology. 2001 Jun;33(6):1353-7 – reference: 16214602 - Lancet. 2005 Oct 8;366(9493):1303-14 – reference: 24867389 - Oncotarget. 2014 May 15;5(9):2839-52 – reference: 24889489 - Ann Surg Oncol. 2014 Nov;21(12):3827-34 – reference: 15123362 - J Hepatol. 2004 Mar;40(3):472-7 – reference: 25608663 - Nat Commun. 2015;6:6087 – reference: 24681130 - J Hepatol. 2014 Jun;60(6):1268-89 – reference: 25140961 - N Engl J Med. 2014 Aug 21;371(8):757-65 – reference: 22824796 - Oncogene. 2013 Jun 20;32(25):3091-100 – reference: 24185509 - Nat Genet. 2013 Dec;45(12):1470-3 – reference: 22420979 - J Hepatol. 2012 Jul;57(1):69-76 – reference: 21808282 - Nat Rev Gastroenterol Hepatol. 2011 Sep;8(9):512-22 – reference: 24122810 - Hepatology. 2014 Apr;59(4):1427-34 |
| SSID | ssj0015932 |
| Score | 2.648765 |
| Snippet | Background.
Challenges in the diagnosis and classification of cholangiocarcinoma have made it difficult to quantify the true incidence of this highly... Challenges in the diagnosis and classification of cholangiocarcinoma have made it difficult to quantify the true incidence of this highly aggressive... The recognized incidence of intrahepatic cholangiocarcinoma in the U.S. continues to rise, whereas the incidence of extrahepatic cholangiocarcinoma is stable.... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 594 |
| SubjectTerms | Adult Aged Aged, 80 and over Bile Duct Neoplasms - epidemiology Bile Ducts, Intrahepatic Cancer of unknown primary Cholangiocarcinoma - epidemiology Epidemiology Extrahepatic cholangiocarcinoma Female Hepatobiliary Humans Incidence Intrahepatic cholangiocarcinoma Male Middle Aged Neoplasms, Unknown Primary - epidemiology Trend United States - epidemiology |
| Title | Forty‐Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1634%2Ftheoncologist.2015-0446 https://www.ncbi.nlm.nih.gov/pubmed/27000463 https://www.proquest.com/docview/1788226181 https://pubmed.ncbi.nlm.nih.gov/PMC4861366 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAviDvlpiDxNqXk4tgLb9AxDaStEm2lwEvkOM4asSVV2zyUF_4658RuLioTg5eoipPY6ffl-Nx8TMhbFQpHJiyzeSikTWEOso_SxLWzRCap9FTq1kVcz87Z6Zx-iYJoMPjVyVqqNslI_vzjupL_QRXOAa64SvYfkG0eCifgN-ALR0AYjjfC-AR05639DWvxtLmtY7RWi4scJqmVzIvySqAQ0HuH7rIa56PpCH0Bn9G1u1DLumzrsY7VmPDB4dd83UsTQkKVRV3kGqiBmumx2Jrk-8kiLzs-hanQYaRptVzlW9G6Ur8vqjaL8jBqyFPJxboT_G_9sR9Bsf-hnfciAav-0vhejZ_CZW1W4EgZ2UpxQzsn6gpfvTzakCzoSNJA7328J-GZTwEWXOXZvDEm6EFfVPsyO7gvr2rgMbaOhdHaKa9JRNw13SK3PbAzULLPJlEThgpAuzVJgdDvu2t6xYLS5jl97WbPZNnPvO1aRLVKM7tP7hlbxPqgifWADFTxkNw5M9kWj0jc8svS_LLywtrnl9XwC9th-Bby673VZZdl2GWV-gpk12MyP_k0G5_aZkMOWwY-p3bgpYKHHpfwBYskdVVKUwomu-Q0UDJkqc-lclgouK9EyDMwBZjMwCZwM5nR1PGfkIOiLNQzYvEwCUE6ZF7mcZp5Xgh6e-okIgg9CSq_HBK2-yNjaarV46YplzFarQBG3AMjRjBiBGNInObGpS7Y8vdb3uyQikG4YsRMFKqs1rHLwQD1GGjBQ_JUI9c8dAf5kPAeps0FWLi931Lki7qAOz0CJZpBv6xG_6bjjCfn4wnWV3p-7WBekLvtt_eSHGxWlXoFWvMmeV0z-zf5tsTk |
| linkProvider | Oxford University Press |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Forty-Year+Trends+in+Cholangiocarcinoma+Incidence+in+the+U.S.%3A+Intrahepatic+Disease+on+the+Rise&rft.jtitle=The+oncologist+%28Dayton%2C+Ohio%29&rft.au=Saha%2C+Supriya+K&rft.au=Zhu%2C+Andrew+X&rft.au=Fuchs%2C+Charles+S&rft.au=Brooks%2C+Gabriel+A&rft.date=2016-05-01&rft.eissn=1549-490X&rft.volume=21&rft.issue=5&rft.spage=594&rft_id=info:doi/10.1634%2Ftheoncologist.2015-0446&rft_id=info%3Apmid%2F27000463&rft.externalDocID=27000463 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1083-7159&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1083-7159&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1083-7159&client=summon |